PD-L1 in cervical cancer
1 EU-approved indication in cervical cancer needs a PD-L1 result: pembrolizumab (advanced).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| PD-L11 | ||||
Keytruda | CPS ≥ 1 | + chemotherapy with or without bevacizumab | Any line advanced | None |
4 approvals for Cervical need no biomarker and apply whatever the result. All approvals for Cervical
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Pembrolizumab (Keytruda)
KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1.